Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $18,500.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating) Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $37.00, for a total transaction of $18,500.00. Following the completion of the transaction, the director now directly owns 85,945 shares in the company, valued at $3,179,965. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of NASDAQ AMPH traded up $0.61 during trading on Thursday, hitting $38.27. 674,420 shares of the company were exchanged, compared to its average volume of 448,419. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 23.39 and a beta of 0.65. Amphastar Pharmaceuticals, Inc. has a 1 year low of $17.56 and a 1 year high of $44.46. The firm’s fifty day moving average price is $36.74 and its 200 day moving average price is $29.26. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.19 and a quick ratio of 2.35.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.36 by $0.11. Amphastar Pharmaceuticals had a net margin of 17.87% and a return on equity of 17.35%. During the same period last year, the firm posted $0.27 EPS. On average, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 1.46 earnings per share for the current year.

Several brokerages have issued reports on AMPH. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Northland Securities boosted their target price on shares of Amphastar Pharmaceuticals from $33.00 to $43.00 in a research report on Monday, April 11th. Piper Sandler boosted their target price on shares of Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 11th. StockNews.com initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Thursday, March 31st. They set a “buy” rating on the stock. Finally, Wells Fargo & Company boosted their target price on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 15th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $37.25.

Institutional investors have recently added to or reduced their stakes in the stock. First Quadrant L P CA purchased a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $36,000. Allworth Financial LP purchased a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $42,000. Lazard Asset Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $42,000. Point72 Hong Kong Ltd purchased a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter worth about $74,000. Finally, Advisor Group Holdings Inc. boosted its position in shares of Amphastar Pharmaceuticals by 314.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock worth $54,000 after buying an additional 1,753 shares in the last quarter. Institutional investors and hedge funds own 59.79% of the company’s stock.

About Amphastar Pharmaceuticals (Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

See Also

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.